Not applicableStudy completedNCT01352585What this trial is testingExploratory Multi-centre Trial In Patients With ET Treated With XAGRID®Who this might be right forEssential Thrombocythemia (ET) Shire 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574What this trial is testingFlonoltinib Maleate Oral Regimens in Patients With MyelofibrosisWho this might be right forMyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more Chengdu Zenitar Biomedical Technology Co., Ltd 105
Not applicableStudy completedNCT01970930What this trial is testingTissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) PatientsWho this might be right forPolycythemia VeraEssential Thrombocythemia Icahn School of Medicine at Mount Sinai 131
Testing effectiveness (Phase 2)Active Not RecruitingNCT04081220What this trial is testingHematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2Who this might be right forThrombocythemia, Essential The University of Texas Health Science Center at San Antonio 9
Large-scale testing (Phase 3)UnknownNCT03662126What this trial is testingKRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentWho this might be right forPrimary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF) Kartos Therapeutics, Inc. 385
Not applicableStudy completedNCT04177576What this trial is testingEvaluation of New Biomarkers of Thrombosis in Myeloproliferative NeoplasmsWho this might be right forMyeloproliferative Neoplasm University Hospital, Bordeaux 397
Not applicableStudy completedNCT00715247What this trial is testingPolycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET GenesWho this might be right forPolycythemia VeraEssential ThrombocythemiaMyelofibrosis University of Utah 726
Testing effectiveness (Phase 2)Ended earlyNCT01668173What this trial is testingHSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ETWho this might be right forMyeloproliferative Neoplasms Memorial Sloan Kettering Cancer Center 7
Large-scale testing (Phase 3)Study completedNCT01467661What this trial is testingLong-term Safety of SPD422 in Japanese Adults With Essential ThrombocythaemiaWho this might be right forEssential Thrombocythemia (ET) Shire 41
Large-scale testing (Phase 3)Study completedNCT02087059What this trial is testingA Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) MyelofibrosisWho this might be right forPrimary Myelofibrosis (MF) Novartis Pharmaceuticals 51
Early research (Phase 1)Study completedNCT00910728What this trial is testingStudy to Assess the Safety of AZD1480 in Patients With Myeloproliferative DiseasesWho this might be right forPrimary Myelofibrosis (PMF)Post-Polycythaemia VeraEssential Thrombocythaemia Myelofibrosis AstraZeneca 65
Not applicableActive Not RecruitingNCT06798805What this trial is testingUnraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative NeoplasmsWho this might be right forEssential Thrombocythemia (ET)Myelofibrosis (MF)Polycythemia Vera (PV) IRCCS Azienda Ospedaliero-Universitaria di Bologna 110
Large-scale testing (Phase 3)Ended earlyNCT02962388What this trial is testingThe Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second LineWho this might be right forEssential Thrombocythemia French Innovative Leukemia Organisation 13
Not applicableStudy completedNCT00433862What this trial is testingMolecular Changes and Biomarkers in Chronic Myeloproliferative DisordersWho this might be right forPolycythemia VeraEssential ThrombocytosisIdiopathic Myelofibrosis+2 more National Institutes of Health Clinical Center (CC) 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT04446650What this trial is testingFedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)Who this might be right forPrimary Myelofibrosis Bristol-Myers Squibb 31
Large-scale testing (Phase 3)Study completedNCT02101268What this trial is testingEfficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFWho this might be right forPrimary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Sierra Oncology LLC - a GSK company 156
Testing effectiveness (Phase 2)Active Not RecruitingNCT05467800What this trial is testingStudy of Canakinumab in Patients With MyelofibrosisWho this might be right forPrimary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisET-MF+2 more John Mascarenhas 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT03441113What this trial is testingExtended Access of Momelotinib in Adults With MyelofibrosisWho this might be right forNeoplasmsPost-polycythemia Vera Myelofibrosis (Post-PV MF)Primary Myelofibrosis (PMF)+2 more GlaxoSmithKline 237
Testing effectiveness (Phase 2)Looking for participantsNCT05835466What this trial is testingReparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)Who this might be right forMyelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF) Icahn School of Medicine at Mount Sinai 10
Testing effectiveness (Phase 2)UnknownNCT04878003What this trial is testingStudy of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisWho this might be right forPrimary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF) Kartos Therapeutics, Inc. 52